Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences Inc. (DTIL) filed this Current Report on Form 8-K on March 18, 2021. The filing announces the financial results for the fourth quarter and the full fiscal year ended December 31, 2020. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for these metrics.
Material Changes
No specific material changes or comparative financial data are detailed within the body of this 8-K filing. Investors must refer to the incorporated press release for year-over-year or quarter-over-quarter comparisons.
Guidance, Outlook, and Risks
The company updated its corporate deck, which is available on the "Investors & Media" section of its website. The filing includes standard disclaimers stating that the information in this report and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 18, 2021) for specific Q4 and full-year 2020 financial figures.
- Access the updated corporate deck on the company's investor website for strategic outlook details.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (DTIL) and exchange (Nasdaq Global Select Market) for the common stock.